Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ilixadencel
- Development stage
- Phase 2
- Lead developer
- Mendus
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intratumoral
01
Overview
Ilixadencel is an off-the-shelf cell-based immunotherapy consisting of allogeneic monocyte-derived dendritic cells (MoDCs) that have been activated to produce pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and interleukin-12 p70. It acts as an immune primer by stimulating the patient’s immune system to recognize and attack tumor cells. Ilixadencel is administered intratumorally and is being developed primarily for use in solid tumors including gastrointestinal stromal tumors (GIST), hepatocellular carcinoma (HCC), soft tissue sarcoma, and previously renal cell carcinoma. The drug has received orphan drug designation for several indications. It was initially developed by Immunicum AB and is now under development by Mendus[1][5][7].
- Other names
- allogeneic proinflammatory dendritic cellsallogeneic monocyte-derived dendritic cells
Beyond the preview
Go deeper on ilixadencel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ilixadencel.